ONCS BRAS |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.02 BRL | -0.14% |
|
-20.59% | -46.00% |
| Sales 2024 * | 6.5B 1.21B | Sales 2025 * | 7.61B 1.42B | Capitalization | 3.57B 666M |
|---|---|---|---|---|---|
| Net income 2024 * | 247M 46.04M | Net income 2025 * | 511M 95.25M | EV / Sales 2024 * | 1.15 x |
| Net Debt 2024 * | 3.93B 733M | Net Debt 2025 * | 3.74B 697M | EV / Sales 2025 * | 0.96 x |
| P/E ratio 2024 * |
14.3
x | P/E ratio 2025 * |
8.21
x | Employees | - |
| Yield 2024 * |
1.28% | Yield 2025 * |
2.32% | Free-Float | 0% |
More Fundamentals
* Assessed data
More news
Latest transcript on ONCS BRAS
| 1 day | -0.14% | ||
| 1 week | -20.59% | ||
| Current month | -21.56% | ||
| 1 month | +0.57% | ||
| 3 months | -30.77% | ||
| 6 months | -38.42% | ||
| Current year | -46.00% |
1 week
6.86
8.76
1 month
5.519.72
Current year
5.3812.95
1 year
5.3813.00
3 years
4.0319.62
5 years
4.0319.62
10 years
4.0319.62
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 55 | 10-01-09 | |
| Director of Finance/CFO | 44 | - | |
| Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 55 | - | |
| Founder | 55 | 10-01-09 | |
| Director of Finance/CFO | 44 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.01% | 4 M€ | -4.41% | - | |
| 0.00% | 32 M€ | +4.01% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-10 | 7.02 | -0.14% | 1 030 600 |
| 24-06-07 | 7.03 | -2.77% | 2,628,600 |
| 24-06-06 | 7.23 | -0.96% | 10,856,400 |
| 24-06-05 | 7.3 | -11.41% | 7,087,700 |
| 24-06-04 | 8.24 | -6.79% | 3,163,700 |
Delayed Quote Sao Paulo, June 10, 2024 at 11:49 am EDT
More quotes
Oncoclinicas do Brasil Servicos Medicos SA is a Brazil-based company engaged in the outpatient medical services sector. The company provides of medical services focused on Oncology. The Company, since its foundation, in addition to acting directly in the treatment of cancer patients, has dedicated itself to the study and identification of the appropriate therapy opportunities for patients and the growth trends in the sector. The company holds interest in a number of subsidiaries, such as Centro de Quimioterapia Antiblastica e Imunoterapia SA, Centro Mineiro de Infusoes SA, and Centro Paulista de Oncologia SA.
Sector
-
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
7.03
BRL
Average target price
13.69
BRL
Spread / Average Target
+94.70%
EPS Revisions
- Stock Market
- Equities
- ONCO3 Stock
